RP-182 alleviated obstruction-induced renal fibrosis by reprogramming CD206+ macrophages

Key Points

• RP-182 effectively reduces renal fibrosis by reprogramming CD206+ macrophages, impacting kidney health.
• The intervention suppresses M2 polarization and MMT through the targeting of β-catenin pathways.
• Findings indicate that RP-182 may serve as a promising therapeutic candidate in the treatment of progressive kidney fibrosis.
• This study may highlight a novel approach to managing renal fibrosis, pending further clinical validations.